CL2017002242A1 - Método para tratar un tumor cerebral - Google Patents

Método para tratar un tumor cerebral

Info

Publication number
CL2017002242A1
CL2017002242A1 CL2017002242A CL2017002242A CL2017002242A1 CL 2017002242 A1 CL2017002242 A1 CL 2017002242A1 CL 2017002242 A CL2017002242 A CL 2017002242A CL 2017002242 A CL2017002242 A CL 2017002242A CL 2017002242 A1 CL2017002242 A1 CL 2017002242A1
Authority
CL
Chile
Prior art keywords
brain tumor
treat
plinabulin
administration
treating
Prior art date
Application number
CL2017002242A
Other languages
English (en)
Inventor
Lan Huang
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56880412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of CL2017002242A1 publication Critical patent/CL2017002242A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Se describen en la presente métodos para tratar un tumor cerebral administrando plinabulina. Algunas modalidades se refieren al tratamiento de glioblastoma multiforme mediante la administración de plinabulina.</p>
CL2017002242A 2015-03-06 2017-09-04 Método para tratar un tumor cerebral CL2017002242A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129623P 2015-03-06 2015-03-06
US201562249807P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
CL2017002242A1 true CL2017002242A1 (es) 2018-04-02

Family

ID=56880412

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002242A CL2017002242A1 (es) 2015-03-06 2017-09-04 Método para tratar un tumor cerebral

Country Status (17)

Country Link
US (2) US10076518B2 (es)
EP (1) EP3265091A4 (es)
JP (2) JP6904570B2 (es)
KR (1) KR102623404B1 (es)
CN (1) CN107530340B (es)
AU (2) AU2016229295B2 (es)
BR (1) BR112017018964A2 (es)
CA (1) CA2978679A1 (es)
CL (1) CL2017002242A1 (es)
HK (2) HK1250007A1 (es)
IL (1) IL254262A0 (es)
MX (1) MX2017011375A (es)
MY (1) MY194341A (es)
RU (1) RU2728796C2 (es)
SG (1) SG11201707128TA (es)
WO (1) WO2016144636A1 (es)
ZA (1) ZA201706035B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
MY194341A (en) 2015-03-06 2022-11-29 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
KR20230018545A (ko) 2016-06-06 2023-02-07 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) * 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CA3089226A1 (en) * 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
MX2021000644A (es) * 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
EP4093398A1 (en) * 2020-01-22 2022-11-30 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Abt-751 and ionizing radiation
JP2023521422A (ja) * 2020-04-10 2023-05-24 ランタン ファルマ インコーポレイテッド 脳がん又はｃｎｓがんの治療のためのヒドロキシルウレアメチル－アシルフルベン
WO2022150851A2 (en) * 2021-01-08 2022-07-14 Lantern Pharma Inc. Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
JP2024513505A (ja) * 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (es) 1973-05-11 1975-01-30
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPS6411523A (en) 1987-07-06 1989-01-17 Kawashima Tekko Kk Dish feeder in tableware washing machine
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
ES2119996T3 (es) 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
IL136044A (en) 1997-11-21 2005-08-31 Euro Celtique Sa 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
DE69940191D1 (de) 1998-01-29 2009-02-12 Aventis Pharma Inc VERFAHREN ZUR HERSTELLUNG EINER N-i(ALIPHATHISCH ODER AROMATISCH)CARBONYL -2-AMINOACETAMID-VERBINDUNG UND EINER CYCLISCHEN VERBINDUNG
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
AU752005B2 (en) 1998-03-26 2002-09-05 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6936704B1 (en) 1999-08-23 2005-08-30 Dana-Farber Cancer Institute, Inc. Nucleic acids encoding costimulatory molecule B7-4
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
BR0017067A (pt) 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
RU2269520C2 (ru) 2000-05-09 2006-02-10 Эдфарма, Инк. Соединения пиперазиндиона
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ATE374767T1 (de) 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
BRPI0506655A (pt) 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2521679T3 (es) * 2006-01-18 2014-11-13 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN101909693A (zh) 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
NZ598078A (en) 2009-08-10 2013-07-26 Univ Texas Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy
NO2504364T3 (es) 2009-11-24 2018-01-06
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) * 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
SG11201602637QA (en) 2013-10-11 2016-05-30 Beyondspring Inc Cancer treatment with combination of plinabulin and taxane
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
MY193968A (en) 2015-02-12 2022-11-03 Beyondspring Pharmaceuticals Inc Use of plinabulin in combination with immune checkpoint inhibitors
MY194341A (en) 2015-03-06 2022-11-29 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
KR20230018545A (ko) 2016-06-06 2023-02-07 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
NZ757213A (en) 2017-03-13 2022-01-28 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof

Also Published As

Publication number Publication date
JP6904570B2 (ja) 2021-07-21
WO2016144636A1 (en) 2016-09-15
MX2017011375A (es) 2018-01-23
US20190000841A1 (en) 2019-01-03
ZA201706035B (en) 2019-12-18
US10076518B2 (en) 2018-09-18
RU2728796C2 (ru) 2020-07-31
JP2021091695A (ja) 2021-06-17
MY194341A (en) 2022-11-29
RU2017131448A (ru) 2019-04-08
CA2978679A1 (en) 2016-09-15
JP7264331B2 (ja) 2023-04-25
EP3265091A4 (en) 2018-08-01
KR20170123642A (ko) 2017-11-08
AU2016229295B2 (en) 2021-11-04
US20180042921A1 (en) 2018-02-15
IL254262A0 (en) 2017-10-31
BR112017018964A2 (pt) 2018-05-22
JP2018507245A (ja) 2018-03-15
CN107530340A (zh) 2018-01-02
HK1249051A1 (zh) 2018-10-26
US10357491B2 (en) 2019-07-23
RU2017131448A3 (es) 2019-08-20
SG11201707128TA (en) 2017-09-28
AU2021254549A1 (en) 2021-11-18
EP3265091A1 (en) 2018-01-10
HK1250007A1 (zh) 2018-11-23
KR102623404B1 (ko) 2024-01-11
CN107530340B (zh) 2021-06-08
AU2016229295A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CL2017002242A1 (es) Método para tratar un tumor cerebral
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
EA201790398A1 (ru) Способы лечения заболевания печени
IL272444A (en) Compounds, their salts and methods for treating diseases
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
PH12017500493A1 (en) Combination therapy
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112016017886A2 (pt) grelina ou variantes ou derivados da mesma, e, método para tratamento de uma lesão cerebral leve em um indivíduo
NZ738672A (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
EA201690880A1 (ru) Тетрациклические ингибиторы аутотаксина
MY195000A (en) Method for the treatment of neurological disease
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
HK1253299A1 (zh) 一種通過基因治療治療眼疾病的改進方法
EA201692202A1 (ru) Способы лечения сердечно-сосудистых заболеваний
BR112018073627A2 (pt) método para tratar câncer em um paciente
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
CO7121334A2 (es) Formulaciones vesiculares